What is the recommended thromboprophylaxis for children with nephrotic syndrome, including first‑line anticoagulation and alternative options for high‑risk patients?

Thromboprophylaxis in Children with Nephrotic Syndrome

For children with nephrotic syndrome at high risk for thrombosis (particularly those with cerebral sinovenous thrombosis or recurrent risk factors), prophylactic anticoagulation should be administered during periods of active disease or risk factor recurrence. 1

Risk Stratification and Indications

The decision to initiate thromboprophylaxis hinges on identifying high-risk scenarios:

• Children with CSVT and recurrent risk factors (including nephrotic syndrome) should receive prophylactic anticoagulation at times of risk factor recurrence 1
• Severe hypoalbuminemia (albumin <2.0 g/dL) represents a critical threshold for considering prophylaxis, as this correlates with significantly elevated thrombotic risk 2
• Congenital nephrotic syndrome carries particularly high thrombotic risk and warrants aggressive prophylaxis 3

First-Line Anticoagulation Options

Low-molecular-weight heparin (LMWH) or vitamin K antagonists (VKAs) are the recommended first-line agents based on the American College of Chest Physicians guidelines 1:

LMWH (Enoxaparin) Dosing

• Starting dose: 1.5-2.0 mg/kg/day subcutaneously, divided twice daily for prophylaxis 4
• Critical caveat: Children with congenital nephrotic syndrome require substantially higher doses—nearly double the standard recommendations (3.2-5.07 mg/kg/day)—to achieve therapeutic anti-Factor Xa levels 3
• Monitoring: Target anti-Factor Xa levels of 0.5-1.0 IU/mL for therapeutic anticoagulation; lower targets (0.2-0.4 IU/mL) for prophylaxis 3
• Duration: Continue until nephrotic syndrome achieves remission, with minimum 3 months if thrombosis has occurred 5

VKA (Warfarin) Dosing

• Starting dose: 0.2 mg/kg/day for children 3
• Target INR: 2.0-3.0 for prophylaxis 3
• Monitoring challenge: Achieving stable INRs is difficult in nephrotic syndrome due to altered protein binding and hepatic synthesis abnormalities 3
• Bleeding risk: Supra-therapeutic anticoagulation (INR >5) is associated with significant bleeding events 3

Alternative Prophylaxis Strategies

For Moderate-Risk Patients (Albumin 2.0-3.0 g/dL)

• Aspirin 75 mg once daily can be considered as a less intensive prophylactic option 2
• This approach showed effectiveness in preventing VTE in a cohort study with minimal bleeding complications 2

Emerging Evidence on DOACs

• Direct oral anticoagulants (DOACs) showed similar safety and efficacy to VKAs in a recent retrospective analysis 6
• However, DOACs are not currently recommended in guidelines due to limited pharmacological data in nephrotic syndrome, particularly concerns about altered drug clearance with proteinuria 6
• Consider DOACs only when LMWH and VKAs are contraindicated or impractical 6

Critical Monitoring Parameters

Coagulation profiling should be performed before initiating high-risk interventions:

• Antithrombin III levels: Urinary loss creates deficiency and contributes to hypercoagulability 7
• Albumin levels: Primary determinant of thrombotic risk stratification 2
• Fibrinogen and cholesterol: Elevated levels indicate increased thrombotic risk 7

High-Risk Scenarios Requiring Immediate Prophylaxis

Initiate prophylaxis immediately when:

• Administering albumin infusions (paradoxically increases thrombotic risk) 7
• Using diuretics (known risk factor for arterial thrombosis) 7
• Central venous catheter placement (should be avoided whenever possible) 5
• Hospital admission or acute medical illness 4
• Surgery, active malignancy, or pregnancy 4

Prophylactic antithrombin III infusion should precede albumin administration and diuretic therapy in children with documented AT III deficiency 7

Duration of Therapy

• Minimum 3 months for documented thrombosis 5
• Continue until complete remission of nephrotic syndrome is achieved 5
• First 6 months following diagnosis represents the highest-risk period and warrants consideration for prophylaxis even without documented thrombosis 4

Common Pitfalls to Avoid

• Underestimating required LMWH doses: Standard prophylactic dosing is often inadequate in nephrotic syndrome, particularly congenital forms 3
• Delaying prophylaxis until after albumin infusion: Albumin administration without prior anticoagulation increases thrombotic risk 7
• Inadequate monitoring frequency: Weekly anti-Factor Xa or INR monitoring is necessary initially to achieve stable anticoagulation 3
• Premature discontinuation: Stopping anticoagulation before achieving remission leaves patients vulnerable to thrombosis 5